Literature DB >> 21849695

Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for Mycobacterium tuberculosis detection in clinical samples.

Melissa B Miller1, Elena B Popowitch, Michael G Backlund, Edward P C Ager.   

Abstract

The Cepheid Xpert MTB/RIF research-use-only (RUO) assay and a laboratory-developed test (LDT) targeting IS6110 were evaluated and compared to mycobacterial culture as the gold standard. The performance characteristics of both molecular assays were determined by using 112 specimens from 90 patients, including 89 pulmonary specimens and 23 extrapulmonary specimens. Of the specimens tested, 37 (33%) were culture positive for the Mycobacterium tuberculosis complex; 29 were pulmonary, and 8 were extrapulmonary. Of these culture-positive specimens, 83% of the pulmonary specimens and 50% of the extrapulmonary specimens were smear positive. There was complete concordance between the smear-positive culture-positive specimens, independent of the anatomical site (100% sensitivity). The sensitivity of the MTB/RIF RUO assay for smear-negative specimens was 60% for pulmonary and 75% for extrapulmonary specimens, while the IS6110 LDT sensitivities were 40% and 0%, respectively. There was also complete concordance among the culture-negative specimens tested. Both assays showed 95% specificity, with four culture-negative specimens testing as positive. A review of patient records indicated that there was a high likelihood of the presence of M. tuberculosis complex DNA in the false-positive specimens. Biosafety analysis was performed and showed an acceptable reduction in organism viability using the processing methods described above. Both molecular assays are suitable for the detection of M. tuberculosis isolates in smear-positive pulmonary and extrapulmonary specimens, while the sensitivity of the detection of M. tuberculosis isolates in smear-negative specimens was variable.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849695      PMCID: PMC3187315          DOI: 10.1128/JCM.05212-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

Authors:  Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

3.  Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Catharina Boehme; Elvira Richter
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

4.  Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens.

Authors:  Elizabeth M Marlowe; Susan M Novak-Weekley; Joven Cumpio; Susan E Sharp; Michelle A Momeny; Anna Babst; Jonathan S Carlson; Masae Kawamura; Mark Pandori
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

5.  Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens.

Authors:  Sylvie Armand; Pascale Vanhuls; Guy Delcroix; René Courcol; Nadine Lemaître
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

6.  Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis.

Authors:  Manuel Causse; Pilar Ruiz; Juan Bautista Gutiérrez-Aroca; Manuel Casal
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

7.  Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?

Authors:  Viral Vadwai; Catharina Boehme; Pamela Nabeta; Anjali Shetty; David Alland; Camilla Rodrigues
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

8.  Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay.

Authors:  N Désiré; A Dehée; V Schneider; C Jacomet; C Goujon; P M Girard; W Rozenbaum; J C Nicolas
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

9.  Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum.

Authors:  Nino Mdivani; Haijing Li; Maka Akhalaia; Medea Gegia; Leila Goginashvili; Douglas S Kernodle; George Khechinashvili; Yi-Wei Tang
Journal:  Clin Chem       Date:  2009-07-02       Impact factor: 8.327

10.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

View more
  32 in total

1.  Comparative Study of GeneXpert with ZN Stain and Culture in Samples of Suspected Pulmonary Tuberculosis.

Authors:  Monika Agrawal; Ashish Bajaj; Vinay Bhatia; Sarjana Dutt
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States.

Authors:  Christopher K Lippincott; Melissa B Miller; Elena B Popowitch; Colleen F Hanrahan; Annelies Van Rie
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 4.  Diagnostic dilemmas in retinitis and endophthalmitis.

Authors:  J L Davis
Journal:  Eye (Lond)       Date:  2011-11-25       Impact factor: 3.775

5.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

6.  The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay.

Authors:  M Barnard; N C Gey van Pittius; P D van Helden; M Bosman; G Coetzee; R M Warren
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

Review 7.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 8.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

9.  Comparison of the Xpert MTB/RIF and Cobas TaqMan MTB assays for detection of Mycobacterium tuberculosis in respiratory specimens.

Authors:  Kyung Sun Park; Ji-Youn Kim; Jung Wha Lee; Yu-Yean Hwang; Kyeongman Jeon; Won-Jung Koh; Chang-Seok Ki; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2013-07-17       Impact factor: 5.948

10.  Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid.

Authors:  Grant Theron; Jonny Peter; Richard Meldau; Hoosain Khalfey; Phindile Gina; Brian Matinyena; Laura Lenders; Gregory Calligaro; Brian Allwood; Gregory Symons; Ureshnie Govender; Mashiko Setshedi; Keertan Dheda
Journal:  Thorax       Date:  2013-06-29       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.